Sartorius Stedim Biotech Sees H1 Revenue Growth 61% In CC

(RTTNews) - Sartorius Stedim Biotech expects revenue growth for the first six months ended June 30 to be about 61% in constant currencies with an underlying EBITDA margin in the range of 36.0 to 36.5%. This better-than-expected performance is broad-based across all geographies and is backed by continuously strong order intake, stable supply chains, and expanded production capacities.

Sartorius Stedim Biotech raised its forecast for the full year. All figures are given in constant currencies.

The company now projects consolidated sales growth of about 48% compared to the previous outlook of 38% growth.

The company now expects annual underlying EBITDA margin of about 36% compared to the prior estimation of about 34%.